Last updated on February 2019

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases


Brief description of study

Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been defined, and no consensus exist on criteria for resectability.

In this study colorectal cancer patients with initially unresectable liver-only metastases, as prospectively confirmed by an expert panel according to predefined criteria, will be tested for RAS and BRAF tumor mutation status and selected by location of primary tumor. Patients with RAS or BRAF mutant and/or right sided tumors will be randomised between doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab (schedule 1), and triple chemotherapy (FOLFOXIRI) plus bevacizumab (schedule 2). Patients with RAS AND BRAF wildtype AND left-sided primary tumors will be randomized between doublet chemotherapy (FOLFOX or FOLFIRI) plus either bevacizumab (schedule 1) or panitumumab (schedule 3). Patient imaging will be reviewed for resectability by a central panel, consisting of at least one radiologist and three surgeons every assessment. Central panel review will be performed prior to randomization as well as during treatment, as described in the protocol.

Detailed Study Description

Patients will be stratified for resectability of liver metastases (potentially resectable versus permanently unresectable), serum lactate dehydrogenase (LDH) (normal versus abnormal), BRAF mutation status (wildtype versus mutated), type of neoadjuvant chemotherapy (FOLFIRI versus FOLFOX) and hospital of registration.

Patients with RAS and BRAF wildtype and left-sided primary tumors will be randomised between FOLFOX or FOLFIRI plus either bevacizumab or panitumumab. The choice between FOLFOX or FOLFIRI is to the discretion of the local investigator, however, the treatment is restricted to regimens that are specified in the protocol. Patients with RAS or BRAF mutated and/or right-sided primary tumors will be randomized between FOLFOX/ FOLFIRI (investigator choice) plus bevacizumab or 5FU, irinotecan, oxaliplatin (FOLFOXIRI) plus bevacizumab.

Patients will be evaluated every 8 weeks by CT scan for disease status. The assigned systemic treatment should be continued for at least 6 months or earlier in case of resectability, progression of disease, unacceptable toxicity, or patient refusal. If after 6 months the panel concludes that the patient is still not resectable, it is highly unlikely that resectability will be achieved at all. Therefore the chemotherapy regimen may be reconsidered after 6 months of treatment. These patients should continue with the targeted drug in combination with chemotherapy, but the chemotherapy may be altered into a less toxic schedule such as fluoropyrimidine monotherapy. The targeted drug should be continued until progression or unacceptable toxicity. In patients who will become resectable and undergo secondary surgery of liver metastases, the total duration of preoperative and postoperative treatment together should be 6 months, with the chemotherapy schedule being administered according to the assigned treatment arm. However in these patients the targeted drug (bevacizumab or panitumumab) should not be continued after surgery.

Clinical Study Identifier: NCT02162563

Find a site near you

Start Over

Gelre Ziekenhuis

Apeldoorn, Netherlands
  Connect »

OLVG, locatie West

Amsterdam, Netherlands
  Connect »

Martini Ziekenhuis

Groningen, Netherlands
  Connect »

Waterlandziekenhuis

Purmerend, Netherlands
  Connect »

Jeroen Bosch Ziekenhuis

's Hertogenbosch, Netherlands
  Connect »

UMC Groningen

Groningen, Netherlands
  Connect »

Treant zorggroep

Emmen, Netherlands
  Connect »

Reinier de Graaf

Delft, Netherlands
  Connect »

Catharina Ziekenhuis

Eindhoven, Netherlands
  Connect »

Maasstad Ziekenhuis

Rotterdam, Netherlands
  Connect »

Flevoziekenhuis

Almere, Netherlands
  Connect »

Orbis Medical Center

Sittard - Geleen, Netherlands
  Connect »

Isala Klinieken

Zwolle, Netherlands
  Connect »

Maastricht UMC+

Maastricht, Netherlands
  Connect »

Franciscus Vlietland

Schiedam, Netherlands
  Connect »

St. Anna Ziekenhuis

Geldrop, Netherlands
  Connect »

Spaarne Gasthuis

Haarlem, Netherlands
  Connect »

Bravis Ziekenhuis

Roosendaal, Netherlands
  Connect »

OLVG, locatie Oost

Amsterdam, Netherlands
  Connect »

Meander Medisch Centrum

Amersfoort, Netherlands
  Connect »

Bethesda ziekenhuis

Hoogeveen, Netherlands
  Connect »

Bernhoven

Uden, Netherlands
  Connect »

Deventer Ziekenhuis

Deventer, Netherlands
  Connect »

Radboud UMC

Nijmegen, Netherlands
  Connect »

Tergooi

Hilversum, Netherlands
  Connect »

Sint Jansdal Ziekenhuis

Harderwijk, Netherlands
  Connect »

Bravis Ziekenhuis

Bergen op Zoom, Netherlands
  Connect »

Laurentius Ziekenhuis

Roermond, Netherlands
  Connect »

Antoni van Leeuwenhoek

Amsterdam, Netherlands
  Connect »

BovenIJ Ziekenhuis

Amsterdam, Netherlands
  Connect »

VUMC

Amsterdam, Netherlands
  Connect »

Rode Kruis Ziekenhuis

Beverwijk, Netherlands
  Connect »

Spaarne ziekenhuis

Hoofddorp, Netherlands
  Connect »

Sint Antonius Ziekenhuis

Nieuwegein, Netherlands
  Connect »

Hagaziekenhuis

Den Haag, Netherlands
  Connect »

LUMC

Leiden, Netherlands
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Ikazia Ziekenhuis

Rotterdam, Netherlands
  Connect »

UMC Utrecht

Utrecht, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.